511 related articles for article (PubMed ID: 26395218)
41. Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates.
Choi MJ; Park YK; Peck KR; Ko KS
Int J Antimicrob Agents; 2014 Nov; 44(5):475-6. PubMed ID: 25443890
[No Abstract] [Full Text] [Related]
42. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
[TBL] [Abstract][Full Text] [Related]
43. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.
Punpanich W; Munsrichoom A; Srisarang S; Treeratweeraphong V
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760
[TBL] [Abstract][Full Text] [Related]
44. The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli.
Ayerbe-Algaba R; Gil-Marqués ML; Miró-Canturri A; Parra-Millán R; Pachón-Ibáñez ME; Jiménez-Mejías ME; Pachón J; Smani Y
Int J Antimicrob Agents; 2019 Oct; 54(4):507-512. PubMed ID: 31299296
[TBL] [Abstract][Full Text] [Related]
45. Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates.
Piewngam P; Kiratisin P
Int J Antimicrob Agents; 2014 Nov; 44(5):396-401. PubMed ID: 25442358
[TBL] [Abstract][Full Text] [Related]
46. Colistin susceptibility test evaluation of multiple-resistance-level Pseudomonas aeruginosa isolates generated in a morbidostat device.
Javed M; Ueltzhoeffer V; Heinrich M; Siegrist HJ; Wildermuth R; Lorenz FR; Neher RA; Willmann M
J Antimicrob Chemother; 2018 Dec; 73(12):3368-3374. PubMed ID: 30137346
[TBL] [Abstract][Full Text] [Related]
47. In vitro activities of colistin, imipenem and ceftazidime against drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates in the south of Iran.
Malekzadegan Y; Abdi A; Heidari H; Moradi M; Rastegar E; Sedigh Ebrahim-Saraie H
BMC Res Notes; 2019 May; 12(1):301. PubMed ID: 31138309
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.
Lu Q; Luo R; Bodin L; Yang J; Zahr N; Aubry A; Golmard JL; Rouby JJ;
Anesthesiology; 2012 Dec; 117(6):1335-47. PubMed ID: 23132092
[TBL] [Abstract][Full Text] [Related]
49. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.
Pankuch GA; Lin G; Seifert H; Appelbaum PC
Antimicrob Agents Chemother; 2008 Jan; 52(1):333-6. PubMed ID: 17967915
[TBL] [Abstract][Full Text] [Related]
50. Comparison of E-test and disc diffusion methods for the in vitro evaluation of the antimicrobial activity of colistin in multi-drug resistant Gram-negative Bacilli.
Somily AM
Saudi Med J; 2010 May; 31(5):507-11. PubMed ID: 20464039
[TBL] [Abstract][Full Text] [Related]
51. Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii.
Leu HS; Ye JJ; Lee MH; Su LH; Huang PY; Wu TL; Huang CT
J Microbiol Immunol Infect; 2014 Oct; 47(5):406-11. PubMed ID: 23834782
[TBL] [Abstract][Full Text] [Related]
52. In vitro efficacy of colistin against multi-drug resistant Pseudomonas aeruginosa by minimum inhibitory concentration.
Gill MM; Rao JU; Kaleem F; Hassan A; Khalid A; Anjum R
Pak J Pharm Sci; 2013 Jan; 26(1):7-10. PubMed ID: 23261721
[TBL] [Abstract][Full Text] [Related]
53. Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol.
Wei WJ; Yang HF
Int J Antimicrob Agents; 2017 Mar; 49(3):321-326. PubMed ID: 28167347
[TBL] [Abstract][Full Text] [Related]
54. Acquisition of Tn6018-3' CS regions increases colistin MICs against Acinetobacter baumannii isolates harboring new variants of AbaRs.
Savari M; Ekrami A; Shoja S; Bahador A
Folia Microbiol (Praha); 2017 Sep; 62(5):373-379. PubMed ID: 28238067
[TBL] [Abstract][Full Text] [Related]
55. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: Description of a decade-long trend.
Balkhair A; Al-Muharrmi Z; Al'Adawi B; Al Busaidi I; Taher HB; Al-Siyabi T; Al Amin M; Hassan KS
Int J Infect Dis; 2019 Aug; 85():10-15. PubMed ID: 31100418
[TBL] [Abstract][Full Text] [Related]
56. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City.
Landman D; Kelly P; Bäcker M; Babu E; Shah N; Bratu S; Quale J
J Antimicrob Chemother; 2011 Feb; 66(2):332-4. PubMed ID: 21131322
[TBL] [Abstract][Full Text] [Related]
57. Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates.
Choi MJ; Ko KS
J Antimicrob Chemother; 2014 Jan; 69(1):275-7. PubMed ID: 23997018
[No Abstract] [Full Text] [Related]
58. Antibacterial Properties and Efficacy of LL-37 Fragment GF-17D3 and Scolopendin A2 Peptides Against Resistant Clinical Strains of Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii In Vitro and In Vivo Model Studies.
Farzi N; Oloomi M; Bahramali G; Siadat SD; Bouzari S
Probiotics Antimicrob Proteins; 2024 Jun; 16(3):796-814. PubMed ID: 37148452
[TBL] [Abstract][Full Text] [Related]
59. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.
Li J; Rayner CR; Nation RL; Owen RJ; Spelman D; Tan KE; Liolios L
Antimicrob Agents Chemother; 2006 Sep; 50(9):2946-50. PubMed ID: 16940086
[TBL] [Abstract][Full Text] [Related]
60. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study.
Matthaiou DK; Michalopoulos A; Rafailidis PI; Karageorgopoulos DE; Papaioannou V; Ntani G; Samonis G; Falagas ME
Crit Care Med; 2008 Mar; 36(3):807-11. PubMed ID: 18431267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
